Adage Capital Partners Gp, L.L.C. Janux Therapeutics, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $54.9 Billion
- Q4 2024
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 3,061,750 shares of JANX stock, worth $110 Million. This represents 0.3% of its overall portfolio holdings.
Number of Shares
3,061,750
Previous 2,075,000
47.55%
Holding current value
$110 Million
Previous $94.3 Million
73.9%
% of portfolio
0.3%
Previous 0.17%
Shares
10 transactions
Others Institutions Holding JANX
# of Institutions
228Shares Held
55.1MCall Options Held
687KPut Options Held
357K-
Ra Capital Management, L.P. Boston, MA10.4MShares$373 Million8.99% of portfolio
-
Janus Henderson Group PLC London, X03.56MShares$128 Million0.1% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.52MShares$127 Million7.18% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$84.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.14MShares$76.9 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.5B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...